How long can SK defend Xcopri from generic competition after settlement?

SK Biopharmaceuticals’ reported settlement with MSN suggests it plans to use follow-on patents to extend Xcopri’s U.S. exclusivity beyond the original compound patent expiry in October 2032. The move signals an aggressive franchise-defense strategy as Xcopri generates nearly all of SK’s revenue and still faces other challengers like Aurobindo and Zydus.